NO960309L - Agonister og antagonister for humaninterleukin-10 - Google Patents

Agonister og antagonister for humaninterleukin-10

Info

Publication number
NO960309L
NO960309L NO960309A NO960309A NO960309L NO 960309 L NO960309 L NO 960309L NO 960309 A NO960309 A NO 960309A NO 960309 A NO960309 A NO 960309A NO 960309 L NO960309 L NO 960309L
Authority
NO
Norway
Prior art keywords
agonists
antagonists
human
human interleukin
preparations
Prior art date
Application number
NO960309A
Other languages
English (en)
Other versions
NO960309D0 (no
Inventor
Chuan-Chu Chou
Xia-Yan Cai
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO960309L publication Critical patent/NO960309L/no
Publication of NO960309D0 publication Critical patent/NO960309D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Agonister og antagonister for humant IL-10 er tilveiebrakt ved hjelp av denne oppfinnelsen som er basert på modifikasjon av endene til fullstendig, | humant IL-10. Det er også tilveiebrakt j preparater og fremgangsmåter for til- i førsel eller inhibering av den biolog- iske aktivitet av humant IL-10. Slike preparater kan være anvendbare ved be- handlingen av sykdommer kjennetegnet ved upassende Th-responser. Nuklein- syrer som koder for agonistene og antagonistene, rekombinante vektorer og : transformerte vertsceller som omfatter j slike nukleinsyrer, og fremgangsmåter i for fremstilling av agonistene og 1 antagonistene under anvendelse av de transformerte vertsceller, er også til- veiebrakt.
NO960309A 1993-07-26 1996-01-25 Agonister og antagonister for humaninterleukin-10 NO960309D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9894393A 1993-07-26 1993-07-26
PCT/US1994/008052 WO1995003411A1 (en) 1993-07-26 1994-07-22 Agonists and antagonists of human interleukin-10

Publications (2)

Publication Number Publication Date
NO960309L true NO960309L (no) 1996-01-25
NO960309D0 NO960309D0 (no) 1996-01-25

Family

ID=22271670

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960309A NO960309D0 (no) 1993-07-26 1996-01-25 Agonister og antagonister for humaninterleukin-10

Country Status (17)

Country Link
EP (1) EP0711346A1 (no)
JP (1) JPH08507930A (no)
KR (1) KR960704041A (no)
CN (1) CN1127529A (no)
AU (1) AU681178B2 (no)
CA (1) CA2168110A1 (no)
CZ (1) CZ23396A3 (no)
FI (1) FI960353A (no)
HU (1) HUT73463A (no)
IL (1) IL110413A0 (no)
NO (1) NO960309D0 (no)
NZ (1) NZ269663A (no)
PL (1) PL312718A1 (no)
SG (1) SG43798A1 (no)
SK (2) SK150596A3 (no)
WO (1) WO1995003411A1 (no)
ZA (1) ZA945434B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK283096B6 (sk) 1994-07-05 2003-02-04 Steeno Research Group A/S Imunomodulátory
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
AUPN481295A0 (en) * 1995-08-16 1995-09-07 Medvet Science Pty. Ltd. Agonists of haemopoietic growth factors
WO1997026278A1 (en) 1996-01-18 1997-07-24 Steeno Research Group A/S Synthetic il-10 analogues
DE19851675A1 (de) * 1998-11-10 2000-05-11 Bayer Ag Menschliche Interleukin-10 Mutantenproteine
EP1283722A1 (en) 2000-03-31 2003-02-19 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
ES2367891T3 (es) 2000-09-29 2011-11-10 Schering Corporation Interleucina-10 pegilada.
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
EP1712241A1 (en) 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Composition for treating cancer adapted for intra-tumoral administration and uses thereof
EP1885863B1 (en) 2005-05-31 2014-11-19 The Regents of the University of Colorado, a body corporate Methods for delivering genes
NZ597098A (en) 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
WO2010040105A2 (en) 2008-10-02 2010-04-08 Trubion Pharmaceuticals, Inc. Cd86 antagonist multi-target binding proteins
AU2009333325B2 (en) 2008-12-17 2014-07-10 Merck Sharp & Dohme Corp. Mono- and di-peg IL-10 production; and uses
CN108129574A (zh) 2011-11-08 2018-06-08 Umc乌德勒支控股有限公司 包括白细胞介素10和白细胞介素4的融合蛋白
JP2016519108A (ja) 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１０を疾病及び疾患の治療に用いる方法
WO2014176373A2 (en) * 2013-04-24 2014-10-30 Armo Biosciences, Inc. Interleukin-10 compositions and uses thereof
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
ES2862139T3 (es) 2013-11-11 2021-10-07 Armo Biosciences Inc Procedimientos de uso de Interleucina 10 para el tratamiento de enfermedades y trastornos
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
EP3206713A4 (en) 2014-10-14 2018-06-27 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
US10143726B2 (en) 2014-10-22 2018-12-04 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR20180020141A (ko) 2015-05-28 2018-02-27 아르모 바이오사이언시스 인코포레이티드 암 치료에 사용되는 peg화된 인터류킨-10
MX2018002298A (es) 2015-08-25 2018-07-06 Armo Biosciences Inc Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
GB2600564B (en) 2019-04-19 2024-02-28 Synerkine Pharma B V A fusion protein comprising IL13

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01113229A (ja) * 1987-10-27 1989-05-01 Inahata Kenkyusho:Kk 多孔質ハニカム構成材
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
CA2115060C (en) * 1991-08-06 2003-05-06 Rene De Waal Malefyt Use of interleukin-10 analogs or antagonists to treat endotoxin- or superantigen induced toxicity

Also Published As

Publication number Publication date
AU681178B2 (en) 1997-08-21
SG43798A1 (en) 1997-11-14
IL110413A0 (en) 1994-10-21
HUT73463A (en) 1996-08-28
WO1995003411A1 (en) 1995-02-02
ZA945434B (en) 1995-01-23
CZ23396A3 (en) 1996-05-15
CA2168110A1 (en) 1995-02-02
CN1127529A (zh) 1996-07-24
FI960353A0 (fi) 1996-01-26
NO960309D0 (no) 1996-01-25
SK8396A3 (en) 1997-03-05
PL312718A1 (en) 1996-05-13
AU7399694A (en) 1995-02-20
FI960353A (fi) 1996-01-26
JPH08507930A (ja) 1996-08-27
NZ269663A (en) 1997-09-22
EP0711346A1 (en) 1996-05-15
HU9503983D0 (en) 1996-03-28
SK150596A3 (en) 1997-04-09
KR960704041A (ko) 1996-08-31

Similar Documents

Publication Publication Date Title
NO960309L (no) Agonister og antagonister for humaninterleukin-10
RU95115239A (ru) Аналог эритропоэтина
NO952974L (no) G-CSF-analogpreparater og fremgangsmåter
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
DK43890A (da) Nucleinsyre, vektorer og celler indeholdende den, derudfra fremstillede produkter og disses anvendelse
WO2000034317A3 (en) Method for reducing immunogenicity of proteins
NO177678C (no) Fremgangsmåte for fremstilling av et terapeutisk aktivt, rekombinant protein som har ASP-aktivitet, ekspresjonssystem samt DNA som koder for nevnte protein
CA2080462A1 (en) Therapeutic uses of actin-binding compounds
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
NO177716C (no) Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff
DK1025236T3 (da) Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
DE59610632D1 (de) Varianten des humanen rekombinanten interferon-gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität
AU6745287A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
EA200001124A1 (ru) Способ генной терапии
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
ATE374246T1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
NO890174L (no) Rekombinante interleukin-1alfa-polypeptider.
EP0816504A3 (en) Platelet activating factor acetylhdrolase, and gene thereof
PT90739A (pt) Processo para a preparacao de uma proteina dotada de actividade de inibicao de trombina
DK0805204T3 (da) Bitestikel - specifikt receptorprotein og anvendelse heraf
ATE103979T1 (de) Menschliches lymphotoxin.
AU2927689A (en) Cucumber mosaic virus coat protein gene
AU1318797A (en) Peptides and uses thereof for therapy of celiac diseases
DK595187A (da) Minactivin og fremgangsmaade til fremstilling deraf